MAPT and Alzheimer disease: When the association between the levels of CSF biomarkers and AD co-pathology in LBD was examined, the medium/high AD co-pathology group showed significantly higher CSF t-tau levels and lower Aβ1–42 levels compared to the low/no AD co-pathology group; however, CSF p-tau levels did not differ between with and without AD co-pathology in patients with LBD [81].